These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35538014)

  • 21. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
    Elstein D; Haims AH; Zahrieh D; Cohn GM; Zimran A
    Blood Cells Mol Dis; 2014; 53(1-2):56-60. PubMed ID: 24581483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
    Elstein D; Cohn GM; Wang N; Djordjevic M; Brutaru C; Zimran A
    Blood Cells Mol Dis; 2011 Jan; 46(1):119-23. PubMed ID: 20727796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry.
    Nguyen Y; Stirnemann J; Lautredoux F; Cador B; Bengherbia M; Yousfi K; Hamroun D; Astudillo L; Billette de Villemeur T; Brassier A; Camou F; Dalbies F; Dobbelaere D; Gaches F; Leguy-Seguin V; Masseau A; Pers YM; Pichard S; Serratrice C; Berger MG; Fantin B; Belmatoug N; On Behalf Of The French Evaluation Of Gaucher Disease Treatment Committee
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32069933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
    Pastores GM; Turkia HB; Gonzalez DE; Ida H; Tantawy AA; Qin Y; Qiu Y; Dinh Q; Zimran A
    Blood Cells Mol Dis; 2016 Jul; 59():37-43. PubMed ID: 27282565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme Replacement Therapy in a Gaucher Family.
    Erdem N; Buran T; Berber I; Aydogdu I
    J Natl Med Assoc; 2018 Aug; 110(4):330-333. PubMed ID: 30126557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
    Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
    Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
    Zimran A; Pastores GM; Tylki-Szymanska A; Hughes DA; Elstein D; Mardach R; Eng C; Smith L; Heisel-Kurth M; Charrow J; Harmatz P; Fernhoff P; Rhead W; Longo N; Giraldo P; Ruiz JA; Zahrieh D; Crombez E; Grabowski GA
    Am J Hematol; 2013 Mar; 88(3):172-8. PubMed ID: 23339116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Velaglucerase alfa: a new option for Gaucher disease treatment.
    Zimran A
    Drugs Today (Barc); 2011 Jul; 47(7):515-29. PubMed ID: 22013559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States.
    Farahbakhshian S; Inocencio TJ; Poorman G; Wright E; Pathak RR; Bullano M
    J Med Econ; 2022; 25(1):755-761. PubMed ID: 35611840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease.
    Elstein D; Abrahamov A; Oz A; Arbel N; Baris H; Zimran A
    Blood Cells Mol Dis; 2015 Dec; 55(4):415-8. PubMed ID: 26460268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid velaglucerase alfa infusion for Gaucher disease: 5-year data.
    Becker-Cohen M; Szer J; Arbel N; Frydman D; Dinur T; Istaiti M; Revel-Vilk S; Zimran A
    Intern Med J; 2022 Sep; 52(9):1645-1646. PubMed ID: 36100564
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of velaglucerase alfa enzyme replacement therapy on red blood cell properties in Gaucher disease.
    Franco M; Reihani N; Marin M; De Person M; Billette de Villemeur T; Rose C; Colin Y; Moussa F; Belmatoug N; Le Van Kim C
    Am J Hematol; 2017 Sep; 92(9):E561-E563. PubMed ID: 28621801
    [No Abstract]   [Full Text] [Related]  

  • 33. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
    Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A
    Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.
    Zimran A; Altarescu G; Philips M; Attias D; Jmoudiak M; Deeb M; Wang N; Bhirangi K; Cohn GM; Elstein D
    Blood; 2010 Jun; 115(23):4651-6. PubMed ID: 20299511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States.
    Abell K; Chadwell SE; Burrow TA; Becker APP; Bailey L; Steele P; Zhang X; Islas-Ohlmayer M; Bittencourt R; Schwartz IVD; Prada CE
    Am J Med Genet C Semin Med Genet; 2020 Dec; 184(4):1052-1059. PubMed ID: 33277783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gaucher disease and multiple myeloma.
    Costello R; O'Callaghan T; Sébahoun G
    Leuk Lymphoma; 2006 Jul; 47(7):1365-8. PubMed ID: 16923570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of treatment on biclonal gammopathy associated with Gaucher disease.
    Decaux O; Ruelland A; Grosbois B
    J Inherit Metab Dis; 2007 Oct; 30(5):824. PubMed ID: 17879146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
    Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
    van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
    J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
    Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.